Phase 2b study demonstrated greater reductions in inflammatory acne lesions with Ameluz® PDT versus vehicle• 3-hour incubation regimen ...

Please provide your email address to receive an email when new articles are posted on . Denifanstat, a fatty acid synthase inhibitor, was effective in the treatment of moderate to severe acne vulgaris ...

Almirall, S.A. (ALM)a global pharmaceutical company dedicated to medical dermatology announced today that China’s National Medical Products Administration (NMPA) has approved Seysara® (sarecycline ...

SAN MATEO, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A multi-center, prospective, open-label, single arm ...

The treatment of acne ( Table I) [1,2,3,4,5,6] is based upon its severity (mild, moderate, severe) and the type(s) of lesion(s) present (noninflammatory, inflammatory, mixed). In general, the ...

Acne vulgaris is a multifactorial skin disorder marked by inflammatory and non-inflammatory lesions that can cause significant physical and psychological distress. Traditional treatment options, ...

Acne vulgaris is one of the commonest skin disorders, which dermatologists treat and it mainly affects adolescents, though it may appear at any age. Acne by definition is multifactorial chronic ...

Final patient visit marks key milestone for Biofrontera, with top-line results expected Q1 2026 Company plans FDA discussion in Q3 2026 to advance Phase 3 program and potential label expansion More ...

WOBURN, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), received ...

Expert Rev Clin Pharmacol. 2010;13(4):563-580. Currently, isotretinoin is only licensed for the treatment of severe acne. However, in recent years, dermatologists have expanded their indications for ...

Active ingredients: Clindamycin (as phosphate) 1.2%, benzoyl peroxide 2.5%; gel. Indication: Topical treatment of acne vulgaris. Pharmacology: Acanya gel combines the lincosamide antibiotic, ...